Columbia Labs
This article was originally published in The Tan Sheet
Executive Summary
Class action suit filed in summer 2000 alleging company made "materially misleading statements and omissions" about its nonoxynol-9 spermicide-containing Advantage-S and Rx progesterone gel fertility treatment Crinone dismissed May 9. Class action pertained to stockholders purchasing Columbia shares between Nov. 8, 1999 and June 9, 2000. Advantage-S was found to be ineffective at protecting against HIV in a UNAIDS Phase III trial conducted last year (1"The Tan Sheet" July 17, 2000, p. 8)
You may also be interested in...
Nonoxynol-9 Spermicides May Need Review After Clinical Trial Results
Appointment of an outside team of investigators to independently review the nonoxynol-9 data generated by the UNAIDS Phase III efficacy trial in the prevention of male-to-female HIV transmission is being urged by Columbia Laboratories.
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands